Ambrx Biopharma Inc ADR (AMAM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2023 | 03-2023 | 12-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -33,128 | -15,302 | N/A | -51,489 | -22,647 |
| Depreciation Amortization | 407 | 66 | N/A | 1,045 | 558 |
| Accounts receivable | 295 | 314 | N/A | -227 | -237 |
| Accounts payable and accrued liabilities | 3,154 | 3,886 | N/A | 861 | -920 |
| Other Working Capital | 414 | -382 | N/A | -4,069 | -8,373 |
| Other Operating Activity | 2,741 | -1,549 | 0 | 13,684 | 5,955 |
| Operating Cash Flow | $-26,117 | $-12,967 | $N/A | $-40,195 | $-25,664 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 39,518 | 29,554 | N/A | -63,301 | N/A |
| PPE Investments | -783 | N/A | N/A | -903 | -774 |
| Investing Cash Flow | $38,735 | $29,554 | $N/A | $-64,204 | $-774 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 166,000 | 166,000 |
| Common Stock Issued | 160,803 | 77,780 | N/A | 102 | 7 |
| Other Financing Activity | -932 | -559 | 0 | -166,136 | -166,013 |
| Financing Cash Flow | $159,871 | $77,221 | $N/A | $-34 | $-6 |
| Beginning Cash Position | 56,441 | 56,441 | N/A | 170,906 | 170,906 |
| End Cash Position | 228,930 | 150,249 | N/A | 66,473 | 144,462 |
| Net Cash Flow | $172,489 | $93,808 | $N/A | $-104,433 | $-26,444 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,117 | -12,967 | N/A | -40,195 | -25,664 |
| Capital Expenditure | -783 | N/A | N/A | -903 | -774 |
| Free Cash Flow | -26,900 | -12,967 | 0 | -41,098 | -26,438 |